Skip Navigation
Menu
Ideas and Opinions |4 December 2018

More Evidence to Help Guide Decision Making About Aspirin for Primary Prevention

Michael Pignone, MD, MPH; Darren A. DeWalt, MD, MPH

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 27 November 2018.
  • Dell Medical School, University of Texas, Austin, Texas (M.P.)
    University of North Carolina School of Medicine, Chapel Hill, North Carolina (D.A.D.)

    Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-2637.

    Corresponding Author: Michael Pignone, MD, MPH, Department of Internal Medicine, Dell Medical School, DMS Health Discovery Building, Room 7.70, 1701 Trinity Street, Stop Z0900, Austin, TX 78712; e-mail, pignone@austin.utexas.edu.

    Current Author Addresses: Dr. Pignone: Department of Internal Medicine, Dell Medical School, DMS Health Discovery Building, Room 7.70, 1701 Trinity Street, Stop Z0900, Austin, TX 78712.

    Dr. DeWalt: UNC Chapel Hill, 5045 Old Clinic Building, CB 7110, Chapel Hill, NC 27516.

    Author Contributions: Conception and design: M. Pignone, D.A. DeWalt.

    Analysis and interpretation of the data: M. Pignone, D.A. DeWalt.

    Drafting of the article: M. Pignone, D.A. DeWalt.

    Critical revision of the article for important intellectual content: M. Pignone, D.A. DeWalt.

    Final approval of the article: M. Pignone, D.A. DeWalt.

    Administrative, technical, or logistic support: M. Pignone.

×
FULL TEXT
Defining the role of aspirin in patients with no history of cardiovascular events (primary prevention) is challenging. Aspirin can have important benefits, including preventing cardiovascular events (1) and possibly reducing the incidence and mortality of some types of cancer (2). However, it can also have important harms, including increasing risk for gastrointestinal bleeding and possibly intracerebral hemorrhage (3). In 2016, the U.S. Preventive Services Task Force examined the body of evidence through a series of systematic reviews and issued a moderate-strength (“B”) recommendation for use of aspirin in “adults aged 50 to 59 years who have a 10% or greater 10-year [cardiovascular disease] risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years” (4).
Despite a relatively large number of trials, interpreting the evidence about aspirin for prevention is difficult because the benefits and downsides are closely balanced. Decision analytic and cost-effectiveness modeling find that aspirin's net health benefit may be good (with the potential for lower total costs) in middle-aged adults at increased cardiovascular risk, especially if aspirin also has a modest or greater effect on cancer mortality (5, 6).
Beyond the challenges in weighing benefits and harms, several important questions remain about the quality of evidence (bias and error) and the possibility that aspirin may work differently in various patient groups (effect modification). Of note, several trials...
FULL TEXT
PDF
Not Available
Citations
Citation

Pignone M, DeWalt DA. More Evidence to Help Guide Decision Making About Aspirin for Primary Prevention. Ann Intern Med. 2018;169:804–805. [Epub ahead of print 27 November 2018]. doi: https://doi.org/10.7326/M18-2637

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2018;169(11):804-805.

DOI: 10.7326/M18-2637

Published at www.annals.org on 27 November 2018

©
2018 American College of Physicians
3 Citations

Related Articles
Review: In newer CVD primary prevention trials, aspirin vs no aspirin does not reduce MI and increases major bleeding
Annals of Internal Medicine; 171 (10): JC55
Individualize Treatment With Aspirin for Primary Prevention
Annals of Internal Medicine; 171 (8): 583-584
Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study
Annals of Internal Medicine; 170 (6): 357-368
Are We There Yet? Another Milepost in the Journey to Identify Appropriate Candidates for Aspirin Primary Prevention
Annals of Internal Medicine; 170 (6): 411-413
View MoreView Less

Journal Club
Review: In newer CVD primary prevention trials, aspirin vs no aspirin does not reduce MI and increases major bleeding
Annals of Internal Medicine; 171 (10): JC55
Review: Aspirin for CVD primary prevention increases gastrointestinal bleeding and hemorrhagic stroke
Annals of Internal Medicine; 165 (4): JC17
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE
Annals of Internal Medicine; 171 (4): JC14
Aspirin before fecal immunochemical testing did not increase sensitivity for detecting advanced colorectal neoplasms
Annals of Internal Medicine; 171 (4): JC20
View MoreView Less

Related Topics
Prevention/Screening

Prevention/Screening.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×